Dated September 17, CHMP Recommends EU Label Expansion For Novartis' Cosentyx In Polymyalgia Rheumatica After Inadequate Glucocorticoid Response Or Relapse During Taper

On September 17, the Committee for Medicinal Products for Human Use (CHMP) recommended the expansion of the EU label for Novartis' Cosentyx to include treatment for polymyalgia rheumatica in patients who have an inadequate response to glucocorticoids or experience a relapse during tapering. This recommendation could enhance the market potential for Cosentyx, which is already established in treating other conditions. The stock ticker for Novartis is NVS.